v3.26.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2025
Summary of Significant Accounting Policies [Abstract]  
Schedule of Computation of Diluted Net Income (Loss) Per Share Anti-Dilutive

The following table presents the Company’s financial liabilities measured at fair value on a recurring basis as of December 31, 2025 and 2024. See Note 7 for a rollforward of the derivative liabilities.

 

    Fair value measured as of December 31, 2025  
Description   Total     Quoted
prices in
active
markets
(Level 1)		     Significant
other
observable inputs
(Level 2)		     Significant
unobservable inputs
(Level 3)		  
Derivative liability – issuance of warrants   $ 347,731     $
-
     $
-
     $ 347,731  
Derivative liability – convertible debt conversion feature     339,196      
-
      
-
       339,196  
Total fair value   $ 686,927      
               -
     $
                 -
       686,927  

 

    Fair value measured as of December 31, 2024 
Description   Total    Quoted
prices in
active
markets
(Level 1)		    Significant
other
observable inputs
(Level 2)		    Significant
unobservable inputs
(Level 3)		 
Derivative liability – issuance of warrants  $
-
   $
-
   $
-
   $
-
 
Derivative liability – convertible debt conversion feature   
-
    
-
    
-
    
-
 
Total fair value  $
           -
    
          -
   $
            -
    
               -
 
Schedule of Computation of Diluted Net Income (Loss) Per Share Anti-Dilutive

The following table presents a summary of outstanding securities considered in the calculation of diluted net income (loss) per share, including a reconciliation of net income (loss) to net income (loss) available to common stockholders for the years ended December 31, 2025 and 2024, as well as securities whose potential dilutive effect was excluded from the computation of diluted net income (loss) per share because their inclusion would have been anti-dilutive.

 

   2025   2024 
Weighted average common shares outstanding used in calculating basic earnings per share   4,930,287    4,800,524 
           
Warrants to purchase Common Stock   64,966    15,096 
Options to purchase Common Stock   2,969,860    2,979,860 
Convertible notes   125,323    
-
 
Series D Preferred Stock   101,565    62,441 
Series C Preferred Stock   1,204,040    1,204,040 
Series B Preferred Stock   1,471,487    1,471,487 
Series A-2 Preferred Stock   442,402    442,402 
Series A-1 Preferred Stock   651,465    651,465 
Series A Preferred Stock   846,368    846,368 
Dilutive effect excluded from earnings per share   (7,877,476)   (7,673,159)
Weighted average common shares used in calculating diluted earnings per share   4,930,287    4,800,524 
Schedule of Revenue by Contract Type

The Company’s revenue by contract type is as follows:

 

   For the Years Ended December 31, 
   2025   2024 
Revenues          
BioCheck  $152,047   $177,283 
OneTest   1,803,707    1,490,881 
CLIAx   89,379    84,179 
Total revenues  $2,045,133   $1,752,343 
Schedule of Contract Liabilities From Contracts With Customers

The following table provides information about contract liabilities from contracts with customers as of December 31, 2025 and 2024.

 

   2025   2024 
OneTest ‒ commercial clients  $350,871   $366,451 
OneTest ‒ individuals   64,000    104,000 
Royalty   41,816    50,000 
Total deferred revenue  $456,687   $520,451 
Less: current portion   (414,871)   (470,451)
Long-term deferred revenue  $41,816    50,000 
Schedule of Contract Liabilities

Significant changes in the contract liabilities balance during the period are as follows:

 

   Contract Liabilities 
Balance, December 31, 2024  $520,451 
Non-cancelable contracts with customers entered during the period   1,423,724 
Revenue recognized related to non-cancelable contracts with customers during the period   (1,487,488)
Balance, December 31, 2025  $456,687